Categories: News

Asia Green Biotechnology Corp. Announces Filing of Financial Statements on SEDAR

[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES]

CALGARY, AB / ACCESSWIRE / May 24, 2024 / Asia Green Biotechnology Corp. (“Asia Green” or the “Company”) (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, May 8, 2024, and May 10, 2024, the Company has filed the following continuous disclosure documents (collectively, the “Documents”) on SEDAR:

  • the Company’s Annual Audited Financial Statements for the year ended December 31, 2023, as required by section 4.2 of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”); and
  • the Company’s Management Discussion & Analysis for the year ended December 31, 2023, as required by section 5.1(2) of NI 51-102.
  • CEO and CFO certificates relating to the Audited Annual Financial Statements, as required by NI 52-109.

It is expected that the Management Cease Trade Order (“MCTO”) issued by the Alberta Securities Commission (“ASC”) on May 8, 2024, will now be lifted.

In addition, the Company also announced today that Vincent Ghazar has resigned from his positions as Chief Financial Officer and Director of the Company. Mr. Ghazar will remain with the Company as a consultant providing accountancy services in the near term.

For further information, contact:
Asia Green Biotechnology Corp.
David Pinkman (CEO)
T: 403 863-6034
E: david.pinkman@asiagreenbiotechnology.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Asia Green Biotechnology Corp.

View the original press release on accesswire.com

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

14 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

17 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

17 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

17 hours ago